Ipca Labs

Why is Ipca Laboratories Ltd falling/rising?

As of 05-Aug, Ipca Laboratories Ltd's stock price is rising to 1,766.85, marking a trend reversal after six days of decline and outperforming its sector by 5.13%. The company has shown strong financial fundamentals, including significant profit growth and low debt, contributing to increased investor interest and stock performance.

As of 05-Aug, Ipca Laboratories Ltd's stock price is rising, currently at 1,766.85, reflecting an increase of 84.6 points or 5.03%. This upward movement is notable as it marks a trend reversal after six consecutive days of decline. The stock has outperformed its sector by 5.13% today, indicating strong performance relative to its peers.<BR><BR>The stock's performance today is further highlighted by reaching an intraday high of Rs 1779.5, which is a 5.78% increase. Additionally, there has been a significant rise in investor participation, with delivery volume increasing by 61.29% compared to the 5-day average, suggesting renewed interest from investors.<BR><BR>Financially, Ipca Laboratories Ltd has demonstrated robust fundamentals, having declared positive results for the last eight consecutive quarters. The latest six months showed a profit after tax (PAT) growth of 53.32%, and the return on capital employed (ROCE) is at its highest of 19.55%. Furthermore, the company maintains a low debt-to-equity ratio of 0.03 times, which is favorable for its financial health.<BR><BR>Overall, the combination of a trend reversal, strong financial performance, increased investor participation, and outperformance against the sector contributes to the rising stock price of Ipca Laboratories Ltd.

Which are the latest news on Ipca Labs?

Should I buy, sell or hold Ipca Laboratories Ltd?

How big is Ipca Labs?

As of 10th June, Ipca Laboratories Ltd has a market capitalization of 41,816.00 Cr, with recent net sales of 9,646.33 Cr and a net profit of 1,141.12 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Ipca Laboratories Ltd has a market capitalization of 41,816.00 Cr and is classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 9,646.33 Cr, while the sum of Net Profit for the same period is 1,141.12 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds stand at 6,948.45 Cr, and Total Assets amount to 11,743.63 Cr.

Who are in the management team of Ipca Labs?

The management team of Ipca Labs includes Premchand Godha (Chairman), A K Jain (Managing Director & CFO), Pranay Godha (CEO), and several independent directors, along with Harish P Kamath as Company Secretary. They are responsible for guiding the company and ensuring regulatory compliance.

The management team of Ipca Labs includes the following key members:<BR><BR>1. **Premchand Godha** - Chairman / Executive Director<BR>2. **A K Jain** - Managing Director and also serves as Joint Managing Director & CFO<BR>3. **Pranay Godha** - Executive Director / Managing Director / CEO / Promoter<BR>4. **Prashant Godha** - Executive Director<BR>5. **Anand T Kusre** - Independent Director and Independent Non-Executive Director<BR>6. **Manisha Premnath** - Independent Director and Independent Non-Executive Director<BR>7. **Kamal Kishore Seth** - Independent Director and Independent Non-Executive Director<BR>8. **Narendra Mairpady** - Independent Director and Independent Non-Executive Director<BR>9. **Harish P Kamath** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in steering the company towards its goals and ensuring compliance with regulations.

Who are the peers of the Ipca Labs?

Ipca Labs' peers include Biocon, Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, Ajanta Pharma, Gland Pharma, Glaxosmi. Pharma, J B Chemicals, and Emcure Pharma. In terms of management risk, growth, and capital structure, Ipca Labs is rated average, with a 1-year return of 16.75%, higher than Glaxosmi. Pharma but lower than Gland Pharma's 41.13%.

Peers: The peers of Ipca Labs are Biocon, Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, Ajanta Pharma, Gland Pharma, Glaxosmi. Pharma, J B Chemicals, and Emcure Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Ajanta Pharma, and Glaxosmi. Pharma, while Good management risk is found at Biocon, Glenmark Pharma, Anthem Bioscienc, Gland Pharma, J B Chemicals, and Emcure Pharma. Average management risk is noted at Ipca Labs, and Below Average management risk is present at Alkem Lab. In terms of Growth, Excellent growth is seen at Anthem Bioscienc, while Average growth is found at Glenmark Pharma and Abbott India, and Below Average growth is noted at Biocon, Alkem Lab, Ipca Labs, Ajanta Pharma, Gland Pharma, Glaxosmi. Pharma, and the rest. For Capital Structure, Excellent capital structure is observed at Alkem Lab, Abbott India, Ipca Labs, Ajanta Pharma, Gland Pharma, Glaxosmi. Pharma, and J B Chemicals, while Good capital structure is seen at Glenmark Pharma and Emcure Pharma, and Below Average capital structure is not present among the peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Gland Pharma at 41.13%, while Glaxosmi. Pharma has the lowest at -36.01%. Ipca Labs has a 1-year return of 16.75%, which is higher than Glaxosmi. Pharma but lower than Gland Pharma. Additionally, Glaxosmi. Pharma is the only peer with a negative six-month return.

What does Ipca Labs do?

Ipca Laboratories Ltd is a mid-cap, fully integrated pharmaceutical company established in 1949, specializing in pharmaceuticals and biotechnology. As of March 2026, it reported net sales of ₹2,388 Cr and a net profit of ₹299 Cr, with a market cap of ₹41,816 Cr.

Overview:<BR>Ipca Laboratories Ltd is a fully integrated pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Mid Cap.<BR><BR>History:<BR>Ipca Laboratories Limited was incorporated on 19 October, 1949, originally named 'The Indian Pharmaceutical Combine Association Limited.' The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 2,388 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 299 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 41,816 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 34.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.12% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 14.93% <BR>Price to Book: 5.14<BR><BR>Contact Details:<BR>Address: 48 Kandivli Industrial Estate, Kandivli (West) Mumbai Maharashtra : 400067 <BR>Tel: 91-22-66474444 <BR>Email: ipca@ipca.co.in/investors@ipca.com <BR>Website: http://www.ipca.com

Are Ipca Laboratories Ltd latest results good or bad?

Ipca Laboratories Ltd's latest results show strong profit growth with a net profit of ₹326.27 crores, up 15.47% quarter-on-quarter and 31.49% year-on-year. However, a 6.42% decline in net sales compared to the previous quarter raises concerns about sustainability, suggesting a mixed performance that warrants caution from investors.

Ipca Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹326.27 crores for Q3 FY26, which reflects a strong growth of 15.47% quarter-on-quarter and an impressive 31.49% year-on-year increase. This indicates solid profitability momentum driven by margin expansion and favorable tax rates.<BR><BR>However, the net sales for the same quarter were ₹2,392.50 crores, showing a decline of 6.42% compared to the previous quarter, although it did see a year-on-year increase of 6.55%. The sequential revenue decline raises concerns about sustainability, especially in light of the company's performance against broader market trends, where it has underperformed the pharmaceutical sector over the past year.<BR><BR>Additionally, while the operating margin improved to 22.29%, the overall mixed performance, characterized by revenue volatility and growth concerns, suggests that investors should approach with caution. The stock's slight decline of 0.20% following the results announcement reflects this investor sentiment.<BR><BR>In summary, while the profit growth is commendable, the revenue decline and underperformance against peers indicate that the results are not entirely positive and warrant careful consideration moving forward.

Is Ipca Labs technically bullish or bearish?

As of December 1, 2025, the technical trend for Ipca Labs is mildly bearish, influenced by weak daily moving averages and monthly indicators, despite a bullish weekly MACD and mildly bullish Bollinger Bands.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating weakness and the monthly MACD showing a mildly bearish outlook. While the weekly MACD is bullish, the overall sentiment is tempered by the monthly indicators, including the KST and Dow Theory, which are also mildly bearish. The Bollinger Bands present a mildly bullish signal on both weekly and monthly time frames, but this is overshadowed by the bearish signals in moving averages and the lack of strong momentum in the RSI. Overall, the technical indicators suggest a cautious approach in the current market environment for Ipca Labs.

How has been the historical performance of Ipca Labs?

Ipca Labs has exhibited consistent growth in net sales and profitability, with net sales increasing from ₹3,773.18 Cr in Mar'19 to ₹8,939.59 Cr in Mar'25, and profit after tax rising from ₹444.03 Cr to ₹787.53 Cr during the same period. The company's financial performance reflects resilience, with improved operating profit and positive cash flow.

Answer:<BR>The historical performance of Ipca Labs shows a consistent growth trajectory in net sales and profitability over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Ipca Labs has demonstrated significant growth in net sales, rising from 3,773.18 Cr in Mar'19 to 8,939.59 Cr in Mar'25. This upward trend is reflected in total operating income, which also increased from 3,773.18 Cr in Mar'19 to 8,939.59 Cr in Mar'25. The total expenditure has risen correspondingly, from 3,081.30 Cr in Mar'19 to 7,213.45 Cr in Mar'25, yet the operating profit (PBDIT) has shown improvement, climbing from 749.56 Cr in Mar'19 to 1,818.94 Cr in Mar'25. Profit before tax has also increased from 548.27 Cr in Mar'19 to 1,131.14 Cr in Mar'25, while profit after tax reached 787.53 Cr in Mar'25, up from 444.03 Cr in Mar'19. The earnings per share (EPS) rose from 35.21 in Mar'19 to 29.08 in Mar'25, indicating a strong performance despite fluctuations in profitability. The company's total assets have expanded from 5,257.82 Cr in Mar'20 to 11,743.63 Cr in Mar'25, with total liabilities increasing from 5,257.82 Cr to 11,743.63 Cr during the same period. Cash flow from operating activities has improved, reaching 1,321.00 Cr in Mar'25 compared to 570.00 Cr in Mar'20, while net cash inflow turned positive at 168.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Ipca Labs has shown resilience and growth in its financial performance over the years.

Is Ipca Labs overvalued or undervalued?

As of September 2, 2025, Ipca Labs is fairly valued with a PE ratio of 39.19, an EV to EBITDA of 19.94, and a PEG ratio of 0.66, making it an attractive investment compared to its peers, Sun Pharma and Divi's Lab, which are considered expensive.

As of 2 September 2025, the valuation grade for Ipca Labs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 39.19, an EV to EBITDA of 19.94, and a PEG ratio of 0.66, indicating a relatively attractive growth potential compared to its price.<BR><BR>In comparison to its peers, Ipca Labs stands out with a fair valuation while Sun Pharma is considered expensive with a PE of 32.69 and Divi's Lab is very expensive with a PE of 70.48. Notably, the company's return over the past year has been slightly better than the Sensex, which aligns with its fair valuation status. Overall, Ipca Labs presents a balanced investment opportunity within the pharmaceuticals and biotechnology sector.

Who are the top shareholders of the Ipca Labs?

The top shareholders of Ipca Labs include promoters holding 21.47%, mutual funds with a collective 29.63% (led by HDFC Mid-cap Opportunities Fund at 8.47%), foreign institutional investors at 10.76%, and individual investors at 6.81%.

The top shareholders of Ipca Labs include a mix of promoters, mutual funds, and foreign institutional investors. The majority shareholders are the promoters, with Kaygee Investments Private Limited holding the largest share at 21.47%. Mutual funds collectively hold 29.63% through 33 schemes, with HDFC Mutual Fund's HDFC Mid-cap Opportunities Fund being the highest public shareholder at 8.47%. Additionally, foreign institutional investors (FIIs) hold 10.76% of the company, while individual investors account for 6.81%.

When is the next results date for Ipca Labs?

No Upcoming Board Meetings

Has Ipca Labs declared dividend?

Ipca Laboratories Ltd has declared a 200% dividend, amounting to ₹2 per share, with an ex-date of November 27, 2024. The dividend yield is 0.29%, and the company has shown strong total returns over various periods, particularly in the long term.

Ipca Laboratories Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 2 per share<BR>- Ex-date: Nov-27-2024<BR><BR>Dividend Yield: 0.29%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.73%, the dividend return was 0%, resulting in a total return of -9.73%.<BR><BR>Over the past year, the price return was 19.48%, the dividend return was 0.34%, leading to a total return of 19.82%.<BR><BR>In the 2-year period, the price return was 85.62%, the dividend return was 0.82%, culminating in a total return of 86.44%.<BR><BR>For the 3-year period, the price return was 60.69%, the dividend return was 1.12%, resulting in a total return of 61.81%.<BR><BR>In the last 4 years, the price return was 34.76%, the dividend return was 1.79%, leading to a total return of 36.55%.<BR><BR>Over the past 5 years, the price return was 84.96%, the dividend return was 3.14%, resulting in a total return of 88.1%.<BR><BR>Overall, Ipca Laboratories Ltd has declared a significant dividend while also demonstrating strong total returns over various periods, particularly in the longer term. The dividend yield remains modest, indicating a balanced approach between price appreciation and dividend distribution.